Charles River Laboratories International Inc. (NYSE:CRL)’s share price hit a new 52-week high during trading on Monday . The stock traded as high as $89.08 and last traded at $88.29, with a volume of 113,978 shares changing hands. The stock had previously closed at $87.93.

Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, May 5th. Credit Suisse Group AG assumed coverage on shares of Charles River Laboratories International in a report on Monday, June 20th. They set a “neutral” rating and a $84.00 price target on the stock. Gabelli assumed coverage on shares of Charles River Laboratories International in a report on Tuesday, April 26th. They set a “buy” rating and a $96.00 price target on the stock. KeyCorp reiterated a “hold” rating and set a $77.00 price target on shares of Charles River Laboratories International in a report on Sunday, May 22nd. Finally, Barclays PLC upped their price target on shares of Charles River Laboratories International from $60.00 to $65.00 and gave the company an “underweight” rating in a report on Friday, May 20th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $83.90.

The firm has a market capitalization of $4.11 billion and a PE ratio of 26.78. The firm has a 50 day moving average of $84.37 and a 200 day moving average of $79.62.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.10. The firm earned $434.10 million during the quarter, compared to analysts’ expectations of $425.05 million. Equities analysts expect that Charles River Laboratories International Inc. will post $4.39 earnings per share for the current fiscal year.

In related news, Director Richard F. Wallman sold 7,740 shares of Charles River Laboratories International stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $88.00, for a total value of $681,120.00. Following the completion of the transaction, the director now owns 24,190 shares in the company, valued at $2,128,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard F. Wallman sold 2,720 shares of Charles River Laboratories International stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $81.00, for a total transaction of $220,320.00. Following the completion of the transaction, the director now owns 15,430 shares of the company’s stock, valued at approximately $1,249,830. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently modified their holdings of the company. Hodges Capital Management Inc. increased its position in shares of Charles River Laboratories International by 0.4% in the fourth quarter. Hodges Capital Management Inc. now owns 390,676 shares of the company’s stock worth $31,406,000 after buying an additional 1,706 shares in the last quarter. Van Berkom & Associates Inc. increased its stake in shares of Charles River Laboratories International by 5.0% in the fourth quarter. Van Berkom & Associates Inc. now owns 719,334 shares of the company’s stock valued at $57,827,000 after buying an additional 34,470 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Charles River Laboratories International by 7.0% in the fourth quarter. Victory Capital Management Inc. now owns 490,834 shares of the company’s stock valued at $39,458,000 after buying an additional 32,031 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Charles River Laboratories International by 2.6% in the fourth quarter. Principal Financial Group Inc. now owns 150,129 shares of the company’s stock valued at $12,069,000 after buying an additional 3,754 shares in the last quarter. Finally, Morgan Stanley increased its stake in shares of Charles River Laboratories International by 23.3% in the fourth quarter. Morgan Stanley now owns 293,248 shares of the company’s stock valued at $23,573,000 after buying an additional 55,393 shares in the last quarter.

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.